Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tissue Sarcoma

Next Previous
Trial Profile

An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tissue Sarcoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide; Dactinomycin; Doxorubicin; Ifosfamide; Vincristine; Vinorelbine
  • Indications Ewing's sarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms BERNIE
  • Sponsors Roche

Most Recent Events

  • 12 Apr 2023 Results (n=61; from July 2008 to December 2016) assessing the clinical behavior of pediatric non-rhabdomyosarcoma soft tissue sarcomas with distant metastases at onset pediatric adult-type metastatic NRSTS enrolled in the randomized BERNIE study and the single-arm MTS 2008 study, published in the Cancer.
  • 16 Jun 2022 Results of pooled analysis of MTS 2008 study and this study was published in the Journal of Clinical Oncology.
  • 13 Mar 2020 Results (n=49; data cutoff date: 31 May 2015) of primary efficacy analysis of a cohort of paediatric patients with metastatic non-rhabdomyosarcoma soft tissue sarcoma were published in the European Journal of Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top